Precursor cell lymphoblastic leukemia-lymphoma
Drug research and approvals for precursor cell lymphoblastic leukemia-lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 426 studies of precursor cell lymphoblastic leukemia-lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 10 authorised medicines for it.
- Recruiting worldwide: 426
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 10
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology PatientsNCT07938333 · Not reported · Children's Hospital of Orange County · starts Nov 9, 2026
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
- GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07910708 · Phase 1 · Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · starts Aug 4, 2026
- Feasibility and Acceptability of Remote Saliva CollectionNCT07884474 · Not reported · St. Jude Children's Research Hospital · starts Dec 1, 2026
- Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07862010 · Early Phase 1 · Hematology department of the 920th hospital · starts Nov 28, 2025
- Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute…NCT07838714 · Phase 1 · Ruijin Hospital · starts May 13, 2026
- Ph+ ALL in Chinese Children: Diagnosis, Treatment, and SurvivalNCT07813208 · Not reported · The Children's Hospital of Zhejiang University School of Medicine · starts Aug 1, 2025
Approved 19
- MethotrexateDihydrofolate reductase inhibitor
- CytarabineDNA inhibitor
- MercaptopurineAmidophosphoribosyltransferase inhibitor
- BlinatumomabT cell surface glycoprotein CD3 cross-linking agent
- AsparaginaseAsparagine hydrolytic enzyme
- DasatinibTyrosine-protein kinase ABL inhibitor
- PegaspargaseAsparagine hydrolytic enzyme
- Inotuzumab ozogamicinCD22 binding agent
- RituximabB-lymphocyte antigen CD20 binding agent
- ClofarabineRibonucleoside-diphosphate reductase RR1 inhibitor
- ImatinibTyrosine-protein kinase ABL inhibitor
- Asparaginase erwinia chrysanthemiAsparagine hydrolytic enzyme
- PonatinibBcr/Abl fusion protein inhibitor
- CrisantaspaseAsparagine hydrolytic enzyme
- Calaspargase pegolAsparagine hydrolytic enzyme
- NelarabinePrecursor T-cell lymphoblastic leukemia-lymphoma · DNA inhibitor
- ChlorambucilDNA inhibitor
- TisagenlecleucelPrecursor B-cell lymphoblastic leukemia-lymphoma · B-lymphocyte antigen CD19 binding agent
- Obecabtagene autoleucelPrecursor B-cell lymphoblastic leukemia-lymphoma · B-lymphocyte antigen CD19 binding agent
Phase 3 12 of 34
- CyclophosphamideDNA inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- VincristineTubulin inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Fludarabine
- DaunorubicinDNA topoisomerase II alpha inhibitor
- Leucovorin
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- Bortezomib26S proteasome inhibitor
- BusulfanDNA inhibitor
- MitoxantroneDNA topoisomerase II alpha inhibitor
Phase 2 12 of 50
- VenetoclaxApoptosis regulator Bcl-2 inhibitor
- 2-mercaptoethanesulfonic acid
- AlemtuzumabCAMPATH-1 antigen inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- Tucidinostat
- CladribineDNA inhibitor
- NilotinibTyrosine-protein kinase ABL inhibitor
- Brexucabtagene autoleucelB-lymphocyte antigen CD19 binding agent
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
Phase 1 or earlier 12 of 69
- PalbociclibCDK6/cyclin D1 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- Ixazomib26S proteasome inhibitor
- Rimiducid
- IdelalisibPI3-kinase p110-delta subunit inhibitor
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- TanespimycinHeat shock protein HSP90 inhibitor
- NavitoclaxApoptosis regulator Bcl-2 inhibitor
- DeferasiroxIron chelating agent
- ImiquimodToll-like receptor 7 agonist
How its trials ended
1,992 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 501 whose ending is known, 33% met their primary endpoint, 4% missed it and 63% stopped early.
- Completed, result not reported62932%
- Ongoing61331%
- Status unknown24913%
- Met its primary endpoint1668%
- Stopped: other or unclear1578%
- Stopped: enrollment or feasibility794%
- Stopped: sponsor or business decision372%
- Missed its primary endpoint211%
- Stopped: lack of efficacy181%
- Stopped: funding131%
- Stopped: safety101%
| Jul 26, 2024 | Dasatinib Accord HealthcareDasatinib · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Sep 15, 2023 | EnrylazeCrisantaspase | Jazz Pharmaceuticals Ireland Limited | EMA ↗ |
| Jun 28, 2017 | BesponsaInotuzumab ozogamicin · orphan | Pfizer Europe MA EEIG | EMA ↗ |
| Jan 14, 2016 | OncasparPegaspargase | Les Laboratoires Servier | EMA ↗ |
| Jan 14, 2016 | SpectrilaAsparaginase | Medac Gesellschaft fuer klinische Spezialpraeparate mbH | EMA ↗ |
| Nov 23, 2015 | BlincytoBlinatumomab · orphan | Amgen Europe B.V. | EMA ↗ |
| Jun 30, 2013 | Imatinib AccordImatinib · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Nov 20, 2006 | SprycelDasatinib (anhydrous) | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| May 29, 2006 | EvoltraClofarabine | Sanofi B.V. | EMA ↗ |
| Nov 7, 2001 | GlivecImatinib | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA